clinical trials for registration of new medicines · clinical trials for registration of new...
TRANSCRIPT
![Page 1: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/1.jpg)
Clinical Trials for Registration of New Medicines
Becki BINEDELLHoang DANG
MBioEnt Medicines Workshop23Feb2015
![Page 2: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/2.jpg)
DisclaimerThe information within this presentation is based on the presenter’s expertise and experience, and represents the views of the presenters for the purposes of a training workshop
![Page 3: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/3.jpg)
Who are we?
Becki BinedellSr. Clinical Research Associate
Hoang DangClinical Research Associate
![Page 4: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/4.jpg)
Our Agenda History of Good Clinical Practice Guidelines and Regulations Overview of Drug Development Why Clinical Trials?
– Purpose – Phases
Lifecycle of a typical Phase III study Clinical Trial Oversight Issues/Challenges
![Page 5: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/5.jpg)
A history of unethical research Tuskegee (Alabama) Syphilis Study
– 1932 – 1972 WWII: Nazi war crimes in death camps 1960s: Thalidomide
– Prescribed as antiemetic to pregnant women– New borns phocomelia– 50% survival rate
![Page 6: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/6.jpg)
A history of unethical research 1963: NY jewish chronic diseases hospital
injection of cancer cells into transplant patients
1964: NY Willowbrook School hepatitis injections in ‘retarded’ children
![Page 7: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/7.jpg)
Clinical Trial Regulations Nuremberg Code
– End of WWII – set of research ethics principles for human experimentation set as a result of the Subsequent Nuremberg Trials
WMA: Declaration of Helsinki– Adopted in 1964, amended six times since.– 2008 Amendment now published– It is the duty of the physician in medical research
to protect the life, health, privacy and dignity of the human subject.
![Page 8: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/8.jpg)
ICH-GCP ICH-GCP: harmonise the regulations and
guidelines required Who came together?
– Regulatory agency/industry representatives from Europe, Japan and US
Purpose:– Create unified standard / mutual acceptance of
clinical data for drugs, biologics and devices– Remove redundancy /duplication in development
and review process
![Page 9: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/9.jpg)
Brief History: GCP 1995: WHO published Guidelines for Good
Clinical Practice (GCP) for trials on pharmaceutical products
1997: GCP became Topic E6 ICH Who is responsible:
– Sponsor, sites, CROs, ECs, Reg., Participants Encompasses:
– Trial design, conduct, recording, reporting– Ethics + quality
![Page 10: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/10.jpg)
Purpose of Clinical Studies Positive (or negative) data can lead to a
recommendation to use (or not to use) a treatment. Studies can be:– Pragmatic
• determine the efficacy and safety of a medicine in human subjects
• support applications made by pharmaceutical companies to register new medicines for marketing
• guide clinicians as to the best medical practice
– Explanatory• evaluate the biological effects of treatment
![Page 11: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/11.jpg)
IMP development overview
http://www.fda.gov/
![Page 12: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/12.jpg)
Phase I
•20-80 pts; Healthy volunteers•Determine PK/PD and MTD (safety)
Phase II
•200-300 pts•Efficacy, short term side effects, common risks
Phase III
•Hundreds – thousands of pts•Efficacy, overall risk-benefit
Phase IV
•Thousands of pts•Ongoing safety of approved drug
Clinical Trial Phases
![Page 13: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/13.jpg)
New Zealand Clinical Trials Must be reviewed and approved by:
![Page 14: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/14.jpg)
Definitions and Roles Health and Disability Ethics Committee (HDEC)
– Reviews ethical issues relating to studies
Locality– Reviews locality-specific research governance issues
Standing Committee on Therapeutic Trials (SCOTT)– Reviews scientific validity of the study– Relays recommendations to MedSafe
Coordinating Investigator (CI)– Affiliated with NZ site– Lead PI
![Page 15: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/15.jpg)
HDECs
Four Committees:
Northern ANorthern BCentralSouthern
Meeting held every week by one of the four HDECs No costs associated with HDEC review HDEC size of 8 members (5 for quorum)
![Page 16: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/16.jpg)
Online Application Form Secure, password protected online system RED – Research Ethics DB System Any online user can submit the form Responsibility of the lead site Study documents will need to be uploaded before
submission– Coordinating Investigator authorisation must be
obtained
![Page 17: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/17.jpg)
Timelines for approval
HDEC cut off date Decision dueDay 0 Day 15 Day 35
Day after Submission Decision dueDay 0 Day 15 Day 35
• Full review• Physical meeting
• Review of amendments, progress reports, protocol violations• Clock starts day after submission• No physical meeting
Full review cycle:
Expedited review cycle:
![Page 18: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/18.jpg)
Maori review Maori Research Review Committees (MRRC) HDEC review does not constitute
consultation with Maori Up to localities to consult local iwi HDEC does not require evidence of MRRC
approval
![Page 19: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/19.jpg)
Post-Approval items A “post-approval item” is an item submitted for HDEC (or SCOTT) review
through Online Forms in respect of an approved study. Examples of “post-approval items” include:– substantial amendments – annual progress reports– protocol deviations or violations– notifications of conclusion of study– final reports
A substantial amendment is defined as an amendment that is likely to affect to a significant degree any of the following:– the safety or physical or mental integrity of participants– the scientific value of the study– the conduct or management of the study– the quality or safety of any medicine or item used in the study
![Page 20: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/20.jpg)
SCOTT Standing Committee on Therapeutic Trials
Applications made through Online Forms
Site Self-Certification only required for studies where participants are staying overnight or longer during dosing periods
No need to provide SCOTT approval to HDEC (and vice versa)
MedSafe required 6-monthly reports from the Sponsor
![Page 21: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/21.jpg)
Overview of New Zealand and Australia Ethics and Regulatory Environment
CountryPreparation
of Documents
Regulatory Approval Ethics Committee Approvals
Import License
/ Initiatio
n
Parallel or Sequential
Total Timeline
Per legislation Currently achievable
Per legislation
Currently achievable
Per legislation
Currently achievable
Australia 2 weeks
CTN - 10 working days
CTX - 30 (chemical,
pharmaceutical, biological)-
50 working days (medical
devices)
CTN 8-10 working
daysCTX -
variable
60 days 45 days 3 weeks
CTN-Sequential
CTX-Parallel
91- 141 working
days3 months
New Zealand 8 days within 45 days 14 days 1-2 months 21 days NA Parallel 1-2
months1.5
months
![Page 22: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/22.jpg)
…how do we ensure trial patients are safe and confidence in the data?
![Page 23: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/23.jpg)
With what should I be compliant?
ICH/GCP
Local Regulations•FDA•EU Directive•Country
specific guidelines
Protocol•Related
documents
![Page 24: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/24.jpg)
Becki BinedellSr. Clinical Research Associate
![Page 25: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/25.jpg)
Phase III study lifecycleDesign: Randomized, double-blind, placebo-controlled
Aim:To investigate the efficacy, safety and tolerability of
IMP vs. placebo as part of a treatment regimen including peginterferon and ribavirin
Target Population: Genotype 1 hepatitis C-infected subjects
![Page 26: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/26.jpg)
Study overview Number of countries = 24 Number of sites = 180 Number of randomised subjects = 1350
• screening of approximately 1800 subjects in order to achieve 1350 subjects enrolled (25% screening failure rate expected)
CLINICAL FOOTPRINTArgentina - 3 Canada - 8 Mexico - 4 Russia - 13
Australia - 7 France -10 Netherlands - 3 Slovakia - 4
Austria - 3 Germany - 13 New Zealand - 4 Spain - 5
Belgium - 7 Great Britain – 9 Poland - 7 Turkey - 4
Brazil - 9 Israel – 7 Portugal - 6 Ukraine - 4
Bulgaria - 4 Italy - 8 Romania - 3 USA - 35
![Page 27: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/27.jpg)
Investigator costs# of sites Site Set-up costs (fixed) # of subjectsPer Subject costs (variable)
Argentina 3 $12,000 $36,000 30 $9,900 $297,000Australia 7 $12,000 $84,000 70 $9,900 $693,000Austria 3 $12,000 $36,000 30 $9,900 $297,000Belgium 7 $12,000 $84,000 70 $9,900 $693,000Brazil 9 $12,000 $108,000 90 $9,900 $891,000Bulgaria 4 $12,000 $48,000 40 $9,900 $396,000Canada 8 $12,000 $96,000 80 $9,900 $792,000France 10 $12,000 $120,000 100 $9,900 $990,000Germany 13 $12,000 $156,000 130 $9,900 $1,287,000Great Britain 9 $12,000 $108,000 90 $9,900 $891,000Israel 7 $12,000 $84,000 70 $9,900 $693,000Italy 8 $12,000 $96,000 80 $9,900 $792,000Mexico 4 $12,000 $48,000 40 $9,900 $396,000Netherlands 3 $12,000 $36,000 30 $9,900 $297,000New Zealand 4 $12,000 $48,000 40 $9,900 $396,000Poland 7 $12,000 $84,000 70 $9,900 $693,000Portugal 6 $12,000 $72,000 60 $9,900 $594,000Romania 3 $12,000 $36,000 30 $9,900 $297,000Russia 13 $12,000 $156,000 130 $9,900 $1,287,000Slovakia 4 $12,000 $48,000 40 $9,900 $396,000Spain 5 $12,000 $60,000 50 $9,900 $495,000Turkey 4 $12,000 $48,000 40 $9,900 $396,000Ukraine 4 $12,000 $48,000 40 $9,900 $396,000USA 35 $12,000 $420,000 350 $9,900 $3,465,000
180 Total Set-Up Cost$2,160,00
0 1800 Total Subject Cost $17,820,000
![Page 28: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/28.jpg)
Study Management Costs
Project Management and Support $2,400,000Data Management (Vendor) $2,150,000Pharmacovigilance $7,132,000Central Laboratory (Vendor) $6,800,000Cognitive Function (Vendor) $3,200,000ECG (Vendor) $22,000Medical Monitor $55,000IMP supply - formulation/release $643,000Rando/drug distribution (Vendor) $890,000Miscellaneous $192,000
$23,484,000
![Page 29: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/29.jpg)
Clinical Study Costs Cost depends on many factors:
– Is the IP already approved for use?– Number of countries– Number of sites– Drug manufacture– Staff salaries– Vendor costs (CRO, lab, etc.)– Study materials and shipping– Monitoring and site travel– Training meetings– Payments to study participants*
These costs are incurred over several years
![Page 30: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/30.jpg)
Study Management Team Global Project Manager (1) Local Project Managers (4)
Clinical Research Associates (22) Clinical Trial Assistants (3)
• Trial Physicians (PIs, SubIs)• Medical Monitor• Vendor Managers
![Page 31: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/31.jpg)
Direct Contacts and Vendors
STUDY SITE WDC
Central ECG
Data Mgt
IndependentVirology Monitoring
Central Lab
![Page 32: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/32.jpg)
Timelines Important dates for study start:– First subject screened: 18 Sep 10– Target to end screening: end of July 2011
Important dates for study conduct:– First subject treated: end May 2011– Last subject treated: August 2011– Last subject last visit: end Jan 2013– First Interim DB Lock: Mar 2013
![Page 33: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/33.jpg)
Total duration of trial per subject: maximum of 78 weeks
•Screening period:– maximum of 6 weeks
•Treatment period:– 48 weeks
•Follow-Up period:– 24 weeks
Timelines
![Page 34: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/34.jpg)
Patient Recruitment Dilemma
Recruiting in approx 10 months requires fast enrolment
versus
Geographical well-distributed patient population by allowing sufficient time for all sites worldwide
to enroll according to expected start-up timelines
“Competitive Recruitment”
“Controlled Recruitment”
![Page 35: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/35.jpg)
STUDY MILESTONESFeasibility
Country do-abilitySite feasibility
Site SelectionRegulatory and Ethics SubmissionsInvestigator MeetingSite InitiationRoutine MonitoringDatabase LockSite Close Out /study archivingClinical Study Report / FDA submissionFDA Inspection
![Page 36: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/36.jpg)
CLINICAL STUDY MONITORING
CRAs required to monitor sites as part of ICH-GCP requirementsCRA functions:
Ensure rights and the well-being of trial subjects all patients on the study should be eligible and have signed ICF.
On site monitoring / Central monitoringSource Data Verification
The reported trial data are accurate, complete, and verifiable from source documents
Ensures compliance with ICH-GCP, the protocol
![Page 37: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/37.jpg)
The Challenges Pharma/Biotech Industry Face
Pharma industry is shifting clinical trial to where:– Large number of patients/qualified investigators– Good data quality– Cost effective and cost efficient– Significant market potential
Regulatory hurdles have increased– FDA has issued 96 “non-approvable” letters since 2004– NDA rejections have increased by 5-fold– NME approvals down 33% in 2007, lowest number in 27 years
R&D productivity is down– R&D spending has soared but the number of new drugs approved by the FDA is
down
Result:– Reduce Clinical Footprint– Pharma Collboration (eg. Transcelerate)
![Page 38: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/38.jpg)
Emerging Markets
![Page 39: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/39.jpg)
Emerging Market Challenges
Linda Martin, DIA2013
![Page 40: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/40.jpg)
IMP Development Costs
![Page 41: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/41.jpg)
Costs to develop one new drug
• Limited patent window to recoup costs• patent filed on a drug lasts for 20 years
• companies file even before clinical trials• by the time the drug hits the marketplace,
the patent may only have between 8 to 10 years left.
![Page 42: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/42.jpg)
Dramatic change in Study Design
2002 2012Total number of endpoints 7 13Total number of procedures 106 167Total number of eligibility criteria 31 50Total number of countries 11 34Total number of investigative sites 124 196Total number of subjects randomised 597 729Mean number of case report form pages 55 171Total number of data points collected N/A 929,203Average length of clinical trial 460 780
Tufts CSDD, *Medidata
![Page 43: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/43.jpg)
Costs R&D spending from the 12 leading pharmaceutical companies
from 1997 to 2011:– $802 billion to gain approval for just 139 drugs: a
staggering $5.8 billion per drug.
![Page 44: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/44.jpg)
Top 5 Pharma# of Employees Total R&D Spend (USD)
Johnson & Johnson 119,000 $7,500,000,000Pfizer 82,000 $8,000,000,000GlaxoSmithKline 99,000 $7,500,000,000Roche 80,000 $10,000,000,000Novartis 99,000 $8,000,000,000
www.manhattan-institute.org (from 2010 Annual Report)
![Page 45: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/45.jpg)
Top Recruitment Barriers Poor and infeasible protocols Conflicting studies Poor planning and execution Lack of subject incentive to seek alternative
treatments Low public awareness and trust Volunteer concern about safety and
convenience
![Page 46: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/46.jpg)
Health Select Committee ‘Inquiry into improving NZ’s environment to
support innovation through clinical trials’
– Chaired by MP Dr Paul Hutchison
– Govt decisions announced Sept 2011
– 54 recommendations• Simplify and streamline the ethical review process• To ensure regulatory framework is as good as or better than
comparable countries
– 12 months to act
![Page 47: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/47.jpg)
Inquiry into improving NZ’s environment to support innovation through clinical trials (2011): http://www.parliament.nz/resource/0000162010– Ethics systems: slow and bureaucratic– No coordination between DHBs– Friction between Pharmac and pharma
companies– Lack of investment in science, R&D– Lack of modern technical infrastructure
![Page 48: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/48.jpg)
Risk-Based Monitoring Risk-Based Monitoring
– An adaptive approach to clinical trial monitoring that directs monitoring focus and activities to the evolving areas of greatest need which have the most potential to impact subject safety and data quality.
FDA recommends that risk must be:– Identified before the start of the
study, focused on safety and data reliability
– Tailored to the conduct of the protocol to eliminate or mitigate those risks
– Utilize monitoring as an adjunct to other data management tools used to identify early trends and need for re-assessing risks
![Page 49: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/49.jpg)
Why conduct studies in NZ? Diverse patient population Ethnic sub-population English speaking health sector High ethics and well respected physicians Streamlined Ethics and Regulatory process Data Integrity Research Infrastructure
![Page 50: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/50.jpg)
Q+A time
![Page 51: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/51.jpg)
Extra slides
![Page 52: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/52.jpg)
Phase 0 First human models Primary goal is to gather preclinical:
– Pharmacodynamic data (what the drug does to the body)
– Pharmacokinetic data (what the body does to the drugs)
Dose– Small, Sub-therapeutic
Typical Subject #– ~10
Obtains no safety of efficacy data Often skipped for Phase I
![Page 53: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/53.jpg)
Phase I “First in Human” studies Primary endpoints: safety, toxicities, PK/PD,
MTD for Phase II (independent of the study population and secondary parameters)
Healthy volunteers or certain types of patients
Intense study design Exciting, high stress, tight timelines
![Page 54: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/54.jpg)
Phase II IIa (exploratory non-pivotal)
– Primary endpoint: establish efficacy, PD or biological activity
– Usually placebo controlled IIb (definite dose range finding study) in
pts.– Can be used as pivotal studies (rare) – if drug
intended to treat life-threatening or severely debilitating illnesses eg cancer.
Restrictive protocols but easier study design
![Page 55: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/55.jpg)
Phase III IIIa: pivotal study – need statistical
significance/ evidence of efficacy and safety.– Confirmation of safety and efficacy– What claims can be made for post-marketing.
IIIb: support publications rather than registration or label changes– Results not intended to be submitted in
submission dossier IMP helping patients
![Page 56: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/56.jpg)
Phase IV Study starts after approval Intent: support publications Large population group to monitor safety
(pharmacovigilance). Protocol is a lot more relaxed.
![Page 57: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/57.jpg)
What is a Sponsor?An individual, company, institution, or organization which takes responsibility for
– the initiation, – management, and / or – financing
of a clinical trial
![Page 58: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/58.jpg)
Sponsor Responsibilities“The sponsor is responsible for implementing and maintaining quality assurance and quality control systems with written SOPs to ensure that trials are conducted and data generated, documented and reported in compliance with the protocol, GCP and the applicable regulatory requirements.”
ICHGCP5.1.1
![Page 59: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/59.jpg)
ICH/GCP: Investigators responsibilities
Principal Investigator & Qualifications
Compliance with the Protocol
Communication with the IRB/IEC
Informed Consent Process
Source Data and Documents
Safety Reporting
![Page 60: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/60.jpg)
Principal Investigator, Site Staff & Qualifications
Qualified by Education, Training & Experience
Knowledgeable about IP, Trial & related Doc’s
Adequate Resources
PI: SUPERVISE Trial Conduct
Document Delegation of Responsibilities
Document Collection of Data
![Page 61: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/61.jpg)
Communication with the IEC
Approval protocols, ICF, amendments,
IB’s, recruitement materials...
Unique identifiers for documents
Timely information about deviations; safety
issues, trial closure...
![Page 62: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/62.jpg)
Informed Consent Process
![Page 63: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/63.jpg)
Informed Consent EC reviewed and approved prior to use
– Use correct version
Consent from subjects to participate must be without coercion and with full information of study requirements, treatment and side effects
Written consent is documented with signatures of the patient (subject) and the person conducting the consent process (investigator)
Patients must be informed of new information as it becomes available
![Page 64: Clinical Trials for Registration of New Medicines · Clinical Trials for Registration of New Medicines Becki BINEDELL. Hoang DANG. MBioEntMedicines Workshop. 23Feb2015. ... – Trial](https://reader030.vdocuments.net/reader030/viewer/2022011814/5e557e0373ee0909ef3c7327/html5/thumbnails/64.jpg)
Stages of a clinical trial Trial set up
– Submissions of all required docs to Reg. + EC Site Initiation
– train site staff Routine Monitoring from CRAs
– Ensure compliance with ICH-GCP and local requirements
Trial completion– Site close outs– Clinical Study Report